Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly is preparing to seek FDA approval for its newest obesity medication, retatrutide, with a filing planned for 2027. The company's recent data indicates that the drug, described as a triple agonist, has been successful in two additional Phase 3 obesity trials. According to reports from Forbes, participants using the medication lost an average of 56 pounds. Beyond weight reduction, PR Newswire reports that the trials delivered significant improvements in A1C levels for the participants involved in the studies. Multiple financial and pharmaceutical outlets are tracking the development.
Barron's reports that Lilly stock rose following these announcements. Yahoo Finance and FirstWord Pharma both emphasize that the drug has cleared two more trials, which sets the stage for the filing process to begin early next year. BioPharma Dive confirms that the company intends to seek FDA approval based on this newly released data, characterizing the trial results as a triumph for the company's obesity pipeline. This development is significant as it expands Eli Lilly's presence in the weight-loss market through the introduction of a triple agonist mechanism. The focus on both weight loss and A1C improvement suggests the drug targets multiple metabolic markers.
The timing of the filing is critical, as the company aims for a 2027 submission to the FDA, indicating a structured timeline for the drug's potential transition from clinical trials to commercial availability. Observers will now look toward the official FDA filing process scheduled for early next year. The market response, specifically the rise in Lilly stock noted by Barron's, suggests investor confidence in the drug's potential. Future updates will likely center on the finality of the Phase 3 data and the specific requirements the FDA may set for the retatrutide approval process throughout 2027.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 114d ago.
Quick answers
What is the name of the drug and how does it work?
The drug is called retatrutide and is described as a triple agonist.
What were the results of the recent trials?
Participants lost an average of 56 pounds and showed significant improvements in A1C levels.
When does Eli Lilly plan to seek FDA approval?
The company plans to seek approval in 2027, with filing expected early next year.
Coverage (6)
- Lilly Stock Rises. It Plans to Seek Approval for Newest Weight-Loss Drug in 2027 Barron's · 117d ago
- Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing Yahoo Finance · 117d ago
- Latest obesity TRIUMPH for Lilly's retatrutide sets up FDA filing for early next year FirstWord Pharma · 117d ago
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C PR Newswire · 117d ago
- Lilly, with new data, to seek FDA approval of obesity drug retatrutide BioPharma Dive · 117d ago
- Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average Forbes · 117d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.